Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accounts Payables: 2012-2025

Historic Accounts Payables for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $19.6 million.

  • Agios Pharmaceuticals' Accounts Payables rose 14.06% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year increase of 14.06%. This contributed to the annual value of $16.6 million for FY2024, which is 70.17% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Accounts Payables stood at $19.6 million, which was up 11.53% from $17.5 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Accounts Payables high stood at $51.2 million for Q1 2021, and its period low was $7.7 million during Q2 2021.
  • In the last 3 years, Agios Pharmaceuticals' Accounts Payables had a median value of $13.3 million in 2023 and averaged $13.6 million.
  • Per our database at Business Quant, Agios Pharmaceuticals' Accounts Payables surged by 173.82% in 2021 and then slumped by 77.45% in 2022.
  • Agios Pharmaceuticals' Accounts Payables (Quarterly) stood at $16.7 million in 2021, then climbed by 11.47% to $18.6 million in 2022, then crashed by 47.46% to $9.8 million in 2023, then skyrocketed by 70.17% to $16.6 million in 2024, then increased by 14.06% to $19.6 million in 2025.
  • Its last three reported values are $19.6 million in Q3 2025, $17.5 million for Q2 2025, and $13.7 million during Q1 2025.